Similar articles

• Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.

  Schulman S, Lundström T, Wålander K, Billing Clason S, Eriksson H. Schulman S, et al. Thromb Haemost. 2005 Oct;94(4):820-4. Thromb Haemost. 2005. PMID: 16270637 Clinical Trial.
• Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.

  Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S; THRIVE III Investigators. Eriksson H, et al. Thromb Haemost. 2005 Sep;94(3):522-7. Thromb Haemost. 2005. PMID: 16268466 Clinical Trial.
• Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.

  Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S; THRIVE III Investigators. Wåhlander K, et al. Br J Haematol. 2006 Apr;133(1):68-77. doi: 10.1111/j.1365-2141.2006.05960.x. Br J Haematol. 2006. PMID: 16512831
• Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.

  Koscielny J, Kiesewetter H, Jörg I, Harenberg J. Koscielny J, et al. Clin Appl Thromb Hemost. 2007 Jul;13(3):299-307. doi: 10.1177/1076029607302561. Clin Appl Thromb Hemost. 2007. PMID: 17636192 Review.
• A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..

  Mohapatra R, Tran M, Gore JM, Spencer FA. Mohapatra R, et al. Am Heart J. 2005 Jul;150(1):19-26. doi: 10.1016/j.ahj.2005.02.012. Am Heart J. 2005. PMID: 16084146 Review.